Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DJO Launches New EMPOWR 3D Knee Amid Growing Trend Toward Outpatient Total Joint Replacement

Executive Summary

DJO Global Inc. launched its new EMPOWR 3D Knee in November amid the growing trend toward outpatient total joint replacement in younger and more active patients. Advanced implant sizing and modernized instrumentation compared with the legacy 3DKnee system should also drive higher surgeon adoption rates.

You may also be interested in...



Orthopedics: Bracing For Change

Despite ongoing economic pressures, the worldwide orthopedic market grew 3% in 2014, reaching $34.7 billion. Although consolidation continues to cause uncertainty and disruption in this space, manufacturers at this year’s AAOS meeting were upbeat about the future as they brace for changes in the competitive landscape, health care delivery, and reimbursement.

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel